SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/17.01.25 Stock SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/17.01.25
Add to a list
To use this feature you must be a member
Log inSign up

SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/17.01.25 Stock

Warrant

DE000SQ86UJ1

Market Closed - Deutsche Boerse AG 15:36:08 2024-06-28 EDT
0.001 EUR 0.00% Intraday chart for SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/17.01.25
6 months-93.33%
Current year-93.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
More news

Quotes 5-day view

Date Price Change
24-06-28 0.001 0.00%
24-06-27 0.001 0.00%
24-06-26 0.001 0.00%
24-06-25 0.001 0.00%
24-06-24 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 03:36 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
IssuerLogo Issuer Société Générale Société Générale
WKN SQ86UJ
ISINDE000SQ86UJ1
Date issued 2023-02-16
Strike 90 $
Maturity 2025-01-17 (203 Days)
Parity 10 : 1
Emission price 0.41 €
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.38 €
Lowest since issue 0.001 €

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53 USD
Average target price
53.19 USD
Spread / Average Target
+28.09%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant